Adamas Pharmaceuticals Inc Form 8-K December 10, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 7, 2015

Adamas Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

001-36399 (Commission File Number)

42-1560076 (IRS Employer Identification No.)

1900 Powell Street, Suite 750

Emeryville, CA

(Address of principal executive offices)

94608 (Zip Code)

Registrant s telephone number, including area code: (510) 450-3500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Edgar Filing: Adamas Pharmaceuticals Inc - Form 8-K

O	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: Adamas Pharmaceuticals Inc - Form 8-K

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
5.02(b)
Departure of Jeffrey Knapp
On December 7, 2015, Jeffrey Knapp, our Chief Operating Officer, resigned effective January 29, 2016, for personal reasons.
John MacPhee, a member of our board of directors, will provide commercial advisory oversight on an interim basis until a Chief Commercial Officer is named.
2

Edgar Filing: Adamas Pharmaceuticals Inc - Form 8-K

SIGNATURES

Pursuant to the requirements of the	ne Securities Exchange	Act of 1934, the	e Registrant has duly	caused this report to	be signed or	n its behalf b	y the
undersigned hereunto duly author	rized.						

Adamas Pharmaceuticals, Inc.

Dated: December 10, 2015

/s/ Gregory Went Gregory Went Chief Executive Officer By:

3